A study of the potential role of bradykinin antagonists and cannabinoid agonists inattenuatingexperimentally induced allergic airway inflammation in guinea pigs / Mohamed Moustafa Ahmed Elkady ; Supervised Zarif Isaak Girgis , Eman Abdel Monem Abdelrasheed , Olfat Gamil Shaker
Material type:
- دراسة التاثير المحتمل لمضادات البراديكينين و محفزات مستقبلات الكانابينويد فى تثبيط التهاب الشعب الهوائية الناتج عن الحساسية المستحدث معمليا فى خنازير غينيا [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.29.Ph.D.2015.Mo.S (Browse shelf(Opens below)) | Not for loan | 01010110067319000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.29.Ph.D.2015.Mo.S (Browse shelf(Opens below)) | 67319.CD | Not for loan | 01020110067319000 |
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pharmacology
Bronchial asthma has become a major public health in the world. It affects more than 334 million people worldwide. The present study was designed to evaluate the potential role of bradykinin antagonists (R - 715; B1 receptor antagonist and Icatibant; B2 receptor antagonist) and cannabinoid agonists [Arachidonyl - 2' - chloroethylamide (ACEA); CB1 receptor agonist and JWH - 133; CB2 receptor agonist] in treatment of allergic airway inflammation in comparison to dexamethasone and montelukast. Sixty male guinea pigs were allocated into five groups; Group (1): Non - sensitized non- treated, Group (2): Include OVA - sensitized non-treated guinea pigs that were subdivided into the following subgroups: Group (2a): OVA - sensitized saline - challenged non - treated, Group (2b): OVA - sensitized OVA - challenged non - treated. Group (3): Sensitized OVA - challenged vehicle - treated group. Group (4): which was further divided into the following subgroups: Group (4a): OVA -sensitized OVA - challenged R - 715 - treated group. Group (4b): OVA - sensitized OVA - challenged icatibant - treated: Group (4c): OVA-sensitized OVA - challenged ACEA - treated. Group (4d): OVA - sensitized OVA - challenged JWH - 133 treated
Issued also as CD
There are no comments on this title.